Taylor Swift just lost her crown: This college dropout becomes the youngest self-made woman billionaire under 40; who is she?
Tired of too many ads?
Remove Ads
How Lucy Guo Made Her Fortune
Guo's New Ventures
Tired of too many ads?
Remove Ads
A College Dropout Becomes a Billionaire
Taylor Swift's Billionaire Journey
FAQs
American singer and songwriter Taylor Swift , has officially lost her status as the world's youngest self-made female billionaire , as per a report. The title is now officially held by Lucy Guo , a 30-year-old tech entrepreneur , according to Forbes.Guo had co-founded Scale AI at the age of 21, and today, the company is valued at $25 billion, a remarkable 80% increase from its valuation of $13.8 billion just a year ago, as per the report.However, in 2018, following a feud with her co-founder Alexandr Wang, Guo exited Scale AI, according to Forbes. But she retained about 5% stake in the company, and that move now has paid off, making her fortune an estimated $1.25 billion, reported Forbes.When she was asked about the accomplishment, Guo replied saying, 'I don't really think about it much. It's a bit wild,' as quoted in the report.While Wang, who is 28-years-old now, is still the CEO of Scale, as per the report. Guo, meanwhile, launched two companies of her own; Backend Capital, a venture capital firm, and Passes, a platform for creators who have already inked deals with big names such as Shaquille O'Neal, Olivia Dunne, and DJ Kygo, reported Forbes.According to the report, Guo is a college dropout, who is one of just six self-made women billionaires under 40 years-old, and the only one to hit that milestone after leaving the company that made her rich.While, Swift achieved billionaire status in October 2023, but unlike Guo, the Grammy-winning artist made the list mostly through her music and touring and not brand deals or business ventures, reported Forbes.Forbes named Lucy Guo as the official youngest self-made female billionaire.Guo co-founded Scale AI, which is now valued at $25 billion, and she retains a 5% stake in the company, as per Forbes.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
an hour ago
- Economic Times
India should avoid rushing for trade pact with US, warn experts
Synopsis Experts caution India against rushing into a trade deal with the US, potentially compromising crucial sectors like agriculture. The US's aggressive tactics, including imposing tariffs on key partners like the EU, highlight the risk of unbalanced agreements. Despite US pressure, many nations resist one-sided terms, urging India to proceed cautiously and protect its core interests during negotiations. Getty Images India should avoid rushing into a trade deal with the US that compromises core sectors like agriculture, experts on Sunday said, cautioning that Washington is not sparing even its key partners like the EU. The US has shot off letters to 24 countries and the European Union (EU) imposing tariffs that are as high as 50 per cent on Brazil. On its key trading partners like the EU and Mexico, 30 per cent duties have been proposed from August 1. Economic think tank GTRI (Global Trade Research Initiative) said India must recognise that it is not alone in facing US pressure. The US is currently negotiating with over 20 countries and seeking concessions from more than 90. "Yet most are resisting because they see these MASALA (Mutually Agreed Settlements Achieved through Leveraged Arm-twisting) deals for what they are politically driven, transactional demands offering no lasting trade certainty," GTRI Founder Ajay Srivastava said. He added that both the EU and Mexico are major trade partners of the US, and Washington can impose tariffs on them to pressure them into quick deals, India cannot expect a balanced deal. Another trade expert said India should tread cautiously while negotiating the trade pact with the US. The expert added that Trump's trade threat is rapidly losing credibility as despite more than three months of pressure, only two countries -- the UK and Vietnam -- have agreed to the USA's one-sided terms. From Japan and South Korea to the EU and Australia, countries are resisting Trump's trade deals that demand tariff cuts without reciprocal US concessions, mandate guaranteed purchases of American goods, and leave the door open for future tariffs even after a deal is signed, the GTRI said. A team of Indian trade negotiators will soon visit Washington to further talks for the proposed Bilateral Trade Agreement (BTA). "India should stay the course and avoid trading away core sectors like agriculture. A hasty deal under pressure could have irreversible consequences, especially when such agreements may not survive the next shift in US politics," Srivastava said.
Hindustan Times
2 hours ago
- Hindustan Times
Trump Says 200% Pharma Tariffs Are Coming. Wall Street Shrugs.
But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, investors have been cautiously celebrating. Despite a broad stock selloff on Friday, the NYSE Arca Pharmaceutical Index is up around 1% over the past week, compared with a basically flat performance for the S&P 500. That outperformance may seem puzzling, but for Wall Street, the size of the tariff matters less than the timing. The 200% figure lit up cable news chyrons, but investors focused instead on the grace period Trump floated. 'We're going to give people about a year, year and a half to come in, and after that, they're going to be tariffed,' he said. A year and a half is a long runway—and it could turn out to be even longer in practice. In a note titled 'Tariffs Schmariffs,' Jefferies analyst Akash Tewari argues that if the grace period begins some time this year and lasts for a year and a half, companies could continue importing drugs tariff-free until 2027. They could buy even more time if they stockpile during that period to cover demand at least until some time in 2028. That might give them time to build entirely new U.S. manufacturing facilities, which typically takes around four years. This doesn't mean Trump isn't getting what he wants. After all, the tariffs are meant as a threat to push companies to make more of their products in the U.S. And in this case, the threat seems to be working. Since Trump began threatening pharma with tariffs, the industry has moved on two fronts. First, companies have been stockpiling drugs at a furious pace to build a cushion. For instance, the Wall Street Journal reported last month that $36 billion worth of hormone treatments—used in popular obesity and diabetes drugs—have been shipped from Ireland this year, more than double last year's total. Second, the industry has announced major investments in U.S. manufacturing. Some of that may be political posturing, but much of it reflects a real shift. Companies increasingly see no choice but to bring production back, at least for drugs sold to American patients. Eli Lilly, for example, has announced a $27 billion plan to expand manufacturing in the U.S. Making drugs in the U.S.—and registering the intellectual property here—comes with a tax hit. That is a big reason the industry offshored production to low-tax countries like Ireland in the first place. But Trump's 'Big Beautiful Bill' offers some relief to offset the pain. The bill lets companies immediately deduct R&D expenses and equipment purchases and raises the cap on how much interest they can write off—making it a lot cheaper to build new plants at home. The upshot: with more time to prepare and a friendlier tax environment, pharma companies may barely feel the sting of tariffs. Take Merck. The company plans to produce a new version of its blockbuster drug Keytruda in the U.S. Jefferies estimates that with steps like stockpiling, gradually shifting production and trimming some costs, the hit to Merck's earnings from tariffs in 2027 and 2028 could be just 1% to 2%. That is actually better than Jefferies's earlier model for a smaller 25% tariff, which assumed fewer workarounds. The sense of a new normal settling in around Trump's second presidency might help explain why dealmaking has returned to the sector. Merck this past week announced a roughly $10 billion deal to buy Verona Pharma. That followed a series of other deal announcements, including Eli Lilly's $1.3 billion pact to acquire Verve Therapeutics. By the end of Trump's term, the U.S. pharmaceutical supply chain could look very different, with a greater share of innovative drug production happening on American soil. That would be a rare win-win—for the White House and for the industry. Write to David Wainer at
Time of India
2 hours ago
- Time of India
'This would never happen in US': Netizens praise Japanese grandpa's conversation with American man
The internet is a place for many positive things. Every day stories of meet-cutes, surprising friendships, and heart-melting conversations between animals, humans and both reach people through the net and make their day by either making them happy or reminding them of a similar love. Tired of too many ads? go ad free now Recently, a video of an American man striking up a conversation with a Japanese grandpa in Japan is going viral on the social media platform X and the netizens are all for the beautiful bond that is formed by the sharing of the same language between these men of different cultures. "This American dude on his way to his Japanese fluency decides to talk to a local Japanese grandpa, and it turned out to be the most wholesome convo ever 🥹" captioned the post, published by an account titled "Wholesome side of X." In the video, the young American man seemed to be doing a series of videos on "Interviewing people in Japan until I am fluent in Japanese." He panned the camera towards a grandpa sitting on a park bench asking him if he is Japanese to which he affirmed. "I am American but I am studying Japanese," said the American man and proceeded to ask the permission of the Japanese grandpa for a video they could shoot together. The Japanese grandpa introduced himself as 'Nishikawa Takashi' and shared how it was the first time he had ever spoken like this with an American man over a camera. When asked by the man if he was his first foreign friend, he agreed. Then happened the most wholesome part which melted many hearts on the internet where the old grandpa invited the young American for dinner at his house. They took a bus to the grandpa's house where the American man shared a dinner with him and his wife. When he asked if the couple had ever been to America, the grandpa shared that they had visited during the time of their marriage to Hawaii and Los Angeles almost 48 years ago. Tired of too many ads? go ad free now Netizens react to the wholesome video Image credits: X/@itsme_urstruly In a few hours since the video has been posted, it has received 2.9M views, 750 comments and 93K likes. Pointing out the welcoming nature of the Japanese grandpa, a person wrote, "Love Japanese culture and how welcoming they are. This would never happen in the US if roles were flipped." "As someone who just came back from visiting Japan I can definitely say that this excellent 🧵doesn't even begin to describe how kind, disciplined and caring are the Japanese and visiting Japan makes you wonder why the rest of the world doesn't behave the same way. ❤️🇯🇵" added another. Some got emotional seeing the conversation, writing, "This was really interesting 🥹" and 'heart warming - this is goodness' 'The young man was very respectful and his Japanese was actually quite good. Very wholesome interaction and they became friends. ♥️' commended a person on X. Others added that these are the kind of videos that deserve to be more on the internet. 'Nice to see common human courtesy and interaction of different cultures. More of this on the Internet, please.👍' and 'THIS is what was meant for social media.'
